Prostate cryotherapy is successfully used in patients with prostate cancer, either as a primary treatment or second recourse after failure of radiotherapy. Material and method.
A prospective study included patients diagnosed with prostate adenocarcinoma, treated by US-guided transperineal primary prostatic cryotherapy at the Clinical Institute of Urology and Renal Transplantation of Cluj- Napoca and Lukmed Clinic between October —July The Oncura Golden SeedNet 2 system was psa prostate cancer level.
Patient follow-up included clinical examinations and prostate specific antigen PSA determinations at 1, 2, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, and 54 months.
Biochemical recurrence was established after three consecutive incresed levels of PSA. A statistical analysis aimed at investigating whether the Gleason score, tumoral stage, preoperative PSA were prognostic factors of biochemical recurrence. The mean preoperative PSA value standard deviation according to the risk group was 5. Survival rates without biochemical recurrence was The result of the statistical analysis chi square test evidenced a statistically significant relationship between Gleason score, tumoral stage, preoperative PSA and the post-cryotherapy biochemical recurrence.
Last generation prostate cryotherapy is an efficient therapeutic technique for prostate cancer, with a survival rate without recurrence of The ideal candidates for prostate cryotherapy are patients at low risk. Maximal tissular destruction after cryotherapy, as evidenced by the lowest PSA level was recorded after a mean time period of three months after the operation.